EGFR/EGFRvIII + B7-H3 Dual-Target CAR-NK (Beijing Biotech)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameEGFR/EGFRvIII + B7-H3 Dual-Target CAR-NK (Beijing Biotech)
Drug Alias NameEGFR/EGFRvIII + CD276 Dual-Target CAR-NK (Beijing Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-CD276Anti-EGFRvIIIAnti-Epidermal growth factor receptor erbB1
TargetsCD276 antigenEpidermal growth factor receptor variant IIIEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHigh-Grade GliomaGlioblastomaGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsHigh-Grade GliomaGlioblastomaGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A